US FDA Clarifies Expectations For Completeness Assessments For Drug Master Files
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has clarified what it expects to see in drug master file (DMF) completeness assessments for active pharmaceutical ingredients (APIs)1.